

Microfluidics Market by Product (Chip, Sensor, Valve, Pump, Needle), Material (Silicon, Polymer), Application [Diagnostics (Clinical, PoC), Research (Proteomics, Genomics, Cell), Therapeutics (Drug Delivery Wearables)], End User - Global forecast to 2030

Market Report | 2026-01-30 | 326 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The Microfluidics market is projected to reach USD 37.2 Billion by 2030 from USD 24.96 billion in 2025, growing at a CAGR of 8.3% during the forecast period. The microfluidics market is expanding due to a number of important factors. The growing requirement for point-of-care diagnostics is one of the important factors. The necessity for fast and accurate diagnosis has risen due to the increase in chronic diseases like cancer and diabetes, which is propelling the application of microfluidics in healthcare. Furthermore, the use of microfluidic devices is increasing due to innovations in drug delivery, organ-on-a-chip technology, and personalized medicine. Additionally, the market is driven by the rise in proteomics and genomics-associated research.

<https://mnmimg.marketsandmarkets.com/Images/microfluidics-market-img-overview.webp>

"Polymers to account for the largest market share in 2024."

The microfluidics market is propelled by polymers because of their low costs, ease of production and adaptability. Microfluidic device manufacturing often requires polymers such as polydimethylsiloxane (PDMS), polymethyl methacrylate (PMMA), and cyclic olefin copolymer (COC). These polymers are helpful in the fabrication of microfluidic channels and structures. Moreover, as compared to conventional materials like silicon or glass, polymers are easier to mold and also enable cheaper manufacturing costs. The biocompatible property of polymers makes them useful for a variety of medical applications, including medication delivery, lab-on-a-chip, and diagnostics. Due to such advantages, polymers account for the largest share in the microfluidics market.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

"Hospital and Diagnostic Centers to register the highest growth rate in the market during the forecast period." Various significant factors are propelling the growth of hospitals and diagnostic centers in the microfluidics industry. One important factor is the rising requirement for point-of-care diagnostics, as they provides quick, on-site testing that improves patient outcomes. Microfluidics play a major role in this positive outcome as it offers faster and precise result . Moreover, the requirement for efficacious diagnostics in clinical settings has risen due to the increase in infectious diseases like COVID-19. These equipment decreases cost, expedites testing methods, and improve precision and accuracy of diagnosis.

"Asia Pacific to register highest growth rate in the market during the forecast period."

The highest CAGR was recorded in the APAC region during the forecast period of 2024- 2029. Asia Pacific includes India, China, Japan, Australia, South Korea, and RoAPAC. Demand for novel technologies is also on the rise, particularly in China, India, and Japan. The government is striving hard to develop research activities in academic setups. In this regard, the Japanese government has distributed USD 64.26 billion toward its 6th Science and Technology Basic Plan for 2021-2025. The rising incidence of chronic and infectious diseases, coupled with increased interest in early diagnosis and preventive care, has enhanced the utilization of microfluidic devices by tremendous bounds. The pharmaceutical and life sciences sectors, which are fast growing in the region, are also driving the research and development efforts, hence increasing the demand for microfluidics.

A breakdown of the primary participants referred to for this report is provided below:

- By Company Type: Tier 1-30%, Tier 2-42%, and Tier 3- 28%
- By Designation: C-level-- 10%, Director-level-14%, and Others-76%
- By Region: North America-40%, Europe-30%, Asia Pacific-22%, Rest of the World -8%.

Prominent players in this market are Abbott laboratories (US) , Agilent Technologies, Inc. (US), Aignep S.P.A (Italy), biomerieux (France), BD(US), Bio-Rad laboratories, Inc (US), Danaher Corporation (US), Illumina Inc. (US), Parker Hannifin Coporation (US), Thermo Fisher Scientific Inc. (US), SMC Corporation (Japan), IDEX Corporation (US), Fortive Corporation (US), Perkinelmer, Inc. (US), F.Hoffmann-LA Roche Ltd (Switzerland), Standard Biotools Inc. (US), Quidelortho Corporation (US), Hologic Inc. (US), Dolomite Microfluidics (UK) and Elveflow (France).

Research Coverage

The report comprise segmentation that covers end users, products, applications, and geographic regions. It also covers the key drivers, restraints, opportunities, and challenges impacting the growth trajectory of the microfluidics market. The research offers stakeholders an in-depth analysis of market potential and challenges, with a focus on major players and competitive landscapes. Moreover, micromarkets are analysed as per their overall impact to the global microfluidics sector, growth patterns, and potential. The analysis forecasts rise in market segment revenues, focusing on five key regions.

Key Benefits of Buying the Report:

The purpose of this research is to assist both new and existing players in the microfluidics market to assess the sustainability of their investments by providing detailed and knowledgeable information. It offers a dataset to assist in making key decisions. This report's potential to facilitate thorough risk evaluation and provide direction for investment decisions is one of its major benefit. Market segmentation according to end-users and geographical areas is provided in the study, that provides precise analysis and insights. It also provide significant trends, obstacles, opportunities, and drivers, giving stakeholders the information they require to make strategic decisions that help in their long-term growth.

The report provides the insights on the following pointers:

Analysis of the key drivers, restraints, opportunities, and challenges affecting the microfluidics market growth: Innovative technology and increase in prevalence of chronic diseases ; increased cost of devices and stringent regulations ; increase in

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

number of diagnostic centers.

Product Development/Innovation: Overview of technologies, research & development ventures and launch of innovative product & service for the microfluidics industry.

Market Development: Details associated with profitable markets: this research studies the microfluidics business in various geographical regions.

Market Diversification: In-depth understanding of innovative products, unexamined regions, recent developments, and expenditures in the microfluidics market.

Competitive Assessment: Detailed analysis of market share, services and products offered and key strategies adopted by prominent players such as Danaher Corporation (US), Illumina Inc. (US), biomerieux (France), Thermo Fisher Scientific Inc. (US) and Abbott laboratories (US).

Table of Contents:

1	INTRODUCTION	30
1.1	STUDY OBJECTIVES	30
1.2	MARKET DEFINITION	30
1.2.1	INCLUSIONS AND EXCLUSIONS	31
1.3	STUDY SCOPE	32
1.3.1	MARKET COVERED	32
1.3.2	YEARS CONSIDERED	33
1.4	CURRENCY CONSIDERED	33
1.5	STAKEHOLDERS	33
1.6	SUMMARY OF CHANGES	34
2	EXECUTIVE SUMMARY	36
2.1	MARKET HIGHLIGHTS AND KEY INSIGHTS	36
2.2	KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS	38
2.3	DISRUPTIVE TRENDS IN MICROFLUIDICS MARKET	39
2.4	HIGH GROWTH SEGMENTS	40
3	PREMIUM INSIGHTS	42
3.1	ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN MICROFLUIDICS MARKET	42
3.2	MICROFLUIDICS MARKET, BY REGION	43
3.3	MICROFLUIDICS MARKET, BY COUNTRY AND END USER	44
3.4	GEOGRAPHIC SNAPSHOT OF MICROFLUIDICS MARKET	45
4	MARKET OVERVIEW	46
4.1	INTRODUCTION	46
4.2	MARKET DYNAMICS	46
4.2.1	DRIVERS	47
4.2.1.1	Integration of microfluidics with 3D printing	47
4.2.2	E-HEALTH AND DIGITAL DIAGNOSTICS DRIVING MICROFLUIDICS ADOPTION	48
4.2.2.1	Increasing prevalence of chronic diseases fueling POC testing	49
4.2.2.2	Increasing focus on data precision and accuracy	50
4.2.3	RESTRAINTS	50
4.2.3.1	Regulatory and clinical validation barriers	50
4.2.3.2	Material selection for microfluidic devices	50
4.2.4	OPPORTUNITIES	51

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

4.2.4.1	Advancing microfluidics for real-time food safety monitoring	51
4.2.4.2	Rising demand for organ-on-a-chip platforms in precision medicine	52
	?	
4.2.5	CHALLENGES	52
4.2.5.1	Limited adoption of microfluidic devices	52
4.2.5.2	Technical and operational limitations	53
4.3	UNMET NEEDS	53
4.4	INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES	54
4.5	STRATEGIC MOVES BY TIER 1/2/3 PLAYERS	54
5	STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, AND AI ADOPTION	56
5.1	KEY TECHNOLOGIES	56
5.1.1	MICROFABRICATION	56
5.1.2	MATERIAL SCIENCE	57
5.1.3	OPTOFLUIDICS	58
5.2	COMPLEMENTARY TECHNOLOGIES	58
5.2.1	MICRO-ELECTRO-MECHANICAL SYSTEMS (MEMS)	58
5.2.2	WEARABLE & IMPLANTABLE MICROFLUIDICS	58
5.3	PATENT ANALYSIS	59
5.3.1	INNOVATIONS AND PATENT REGISTRATIONS	60
5.4	FUTURE APPLICATIONS	61
5.5	IMPACT OF AI/GENAI ON MICROFLUIDICS MARKET	61
5.5.1	TOP USE CASES AND MARKET POTENTIAL	61
5.5.2	BEST PRACTICES IN MICROFLUIDICS	62
5.5.3	CASE STUDIES OF AI IMPLEMENTATION IN MICROFLUIDICS MARKET	63
5.5.4	INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS	63
5.5.5	CLIENT'S READINESS TO ADOPT GENERATIVE AI IN MICROFLUIDICS MARKET	64
5.6	SUCCESS STORIES AND REAL-WORLD APPLICATIONS	64
5.7	REGULATORY LANDSCAPE	65
5.7.1	NORTH AMERICA	65
5.7.1.1	US	65
5.7.1.2	Canada	66
5.7.2	EUROPE	67
5.7.3	ASIA PACIFIC	68
5.7.3.1	Japan	68
5.7.3.2	China	69
5.7.3.3	India	70
5.7.4	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	71
	?	
6	CUSTOMER LANDSCAPE & BUYER BEHAVIOR	73
6.1	BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA	73
6.1.1	KEY STAKEHOLDERS IN BUYING PROCESS	73
6.1.2	BUYING CRITERIA	74
6.2	DECISION-MAKING PROCESS	75
6.3	ADOPTION BARRIERS & INTERNAL CHALLENGES	75
6.4	UNMET NEEDS FROM END USERS	76
7	INDUSTRY TRENDS	78
7.1	PORTER'S FIVE FORCES ANALYSIS	78

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7.1.1	THREAT OF NEW ENTRANTS	79
7.1.2	THREAT OF SUBSTITUTES	79
7.1.3	BARGAINING POWER OF SUPPLIERS	79
7.1.4	BARGAINING POWER OF BUYERS	79
7.1.5	INTENSITY OF COMPETITIVE RIVALRY	79
7.2	MACROECONOMIC INDICATORS	80
7.2.1	INTRODUCTION	80
7.2.2	HEALTHCARE EXPENDITURE AND INFRASTRUCTURE OUTLOOK	80
7.2.3	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	80
7.2.4	MACROECONOMIC OUTLOOK FOR EUROPE	81
7.2.5	MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	81
7.2.6	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	82
7.2.7	MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA	83
7.2.8	TRENDS IN GLOBAL MICROFLUIDICS INDUSTRY	83
7.3	VALUE CHAIN ANALYSIS	84
7.3.1	RESEARCH & DEVELOPMENT	84
7.3.2	RAW MATERIAL PROCUREMENT & MANUFACTURING	84
7.3.3	MARKETING & SALES, DISTRIBUTION, AND POST-SALES SERVICES	84
7.4	ECOSYSTEM ANALYSIS	85
7.5	PRICING ANALYSIS	87
7.5.1	AVERAGE SELLING PRICE TREND, BY REGION	87
7.5.2	AVERAGE SELLING PRICE OF MICROFLUIDIC COMPONENTS, BY KEY PLAYERS	89
7.6	TRADE DATA ANALYSIS	90
7.6.1	IMPORT DATA (HS CODE 3822)	90
7.6.2	EXPORT DATA (HS CODE 3822)	91
7.7	KEY CONFERENCES & EVENTS, 2026-2027	91
7.8	TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS	92
7.9	INVESTMENT & FUNDING SCENARIO	93
?		
7.10	CASE STUDY ANALYSIS	94
7.10.1	CASE STUDY 1: MULTIPLEX MICROFLUIDIC CIRCUIT FOR BLOOD VESSEL-ON-A-CHIP PERFUSION USING FLOWEZ	94
7.10.2	CASE STUDY 2: MICROFLUIDIC SYSTEM FOR ROBOTIC HAND PLAYING NINTENDO	95
7.10.3	CASE STUDY 3: 3D-PRINTED MICROFLUIDIC DEVICES USING POLYJET TECHNOLOGY	95
7.11	IMPACT OF 2025 US TARIFFS ON MICROFLUIDICS MARKET	96
7.11.1	INTRODUCTION	96
7.11.2	KEY TARIFF RATES	96
7.11.3	PRICE IMPACT ANALYSIS	97
7.11.4	IMPACT ON COUNTRY/REGION	97
7.11.5	IMPACT ON END-USE INDUSTRIES	98
8	MICROFLUIDICS MARKET, BY PRODUCT	99
8.1	INTRODUCTION	100
8.2	MICROFLUIDICS-BASED DEVICES	100
8.2.1	HIGH UPTAKE OF POC TESTING AND ORGAN-ON-A-CHIP SYSTEMS TO DRIVE MARKET	100
8.2.2	POLYMERASE CHAIN REACTION (PCR) SYSTEMS	101
8.2.3	MICROFLUIDIC CAPILLARY ELECTROPHORESIS	102
8.2.4	NEXT-GENERATION SEQUENCING (NGS) SYSTEMS	103
8.2.5	DROPLET & PARTICLE PRODUCTION SYSTEMS	104

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.3 OTHER DEVICES 105
- 8.4 MICROFLUIDIC COMPONENTS 106
 - 8.4.1 CRUCIAL FOR CONTINUOUS HEALTH MONITORING 106
 - 8.4.2 MICROFLUIDIC COMPONENTS, BY TYPE 106
 - 8.4.2.1 Microfluidic chips 107
 - 8.4.2.2 Flow & pressure sensors 109
 - 8.4.2.3 Flow & pressure controllers 110
 - 8.4.2.4 Microfluidic valves 111
 - 8.4.2.5 Micropumps 112
 - 8.4.2.6 Microneedles 112
 - 8.4.2.7 Other microfluidic components 113
 - 8.4.3 MICROFLUIDIC COMPONENTS, BY MATERIAL 114
 - 8.4.3.1 Silicon 114
 - 8.4.3.2 Polymethyl methacrylate (PMMA) 115
 - 8.4.3.3 Polydimethylsiloxane (PDMS) 116
 - 8.4.3.4 Cyclic olefin copolymer (COC) 117
 - 8.4.3.5 Glass 117
 - 8.4.3.6 OTHER MATERIALS 118
- 9 MICROFLUIDICS MARKET, BY APPLICATION 119
 - 9.1 INTRODUCTION 120
 - 9.2 IN VITRO DIAGNOSTICS (IVD) 120
 - 9.2.1 CLINICAL DIAGNOSTICS 121
 - 9.2.1.1 Growing focus on early disease detection to drive market 121
 - 9.2.2 POINT-OF-CARE TESTING (POCT) 122
 - 9.2.2.1 Increasing demand for decentralized infectious disease testing to drive market 122
 - 9.2.3 VETERINARY DIAGNOSTICS 123
 - 9.2.3.1 Rising demand for rapid, field-deployable veterinary diagnostics to drive market 123
 - 9.3 THERAPEUTICS 124
 - 9.3.1 DRUG DELIVERY 125
 - 9.3.1.1 Ability to enable scalable production of polymer-based drug particles to drive market 125
 - 9.3.2 WEARABLE 126
 - 9.3.2.1 Ability to enable proactive management of hydration, metabolic status, and disease biomarkers to drive market 126
 - 9.4 PHARMACEUTICAL & LIFE SCIENCE RESEARCH 127
 - 9.4.1 LAB ANALYTICS 128
 - 9.4.1.1 Proteomic analysis 129
 - 9.4.1.1.1 Utilization of proteomes-on-a-chip devices for therapeutic development to drive market 129
 - 9.4.1.2 Genomic analysis 130
 - 9.4.1.2.1 High-throughput, cost-effective genomic analysis enabled by microfluidics 130
 - 9.4.1.3 Cell-based assays 131
 - 9.4.1.3.1 Microfluidic co-cultures enable precise, high-throughput modeling of complex tissues for drug testing and disease research 131
 - 9.4.1.4 Capillary electrophoresis 132
 - 9.4.1.4.1 Enables high-throughput, precise, and cost-efficient protein and nucleic acid analysis 132
 - 9.4.2 MICRODISPENSING 133
 - 9.4.2.1 Suitability for low-viscosity applications to support market growth 133
 - 9.4.3 MICROREACTORS 134

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.4.3.1 Growing adoption of continuous flow synthesis in research & development to drive market 134
- ?
- 10 MICROFLUIDICS MARKET, BY END USER 135
 - 10.1 INTRODUCTION 136
 - 10.2 HOSPITALS & DIAGNOSTIC CENTERS 137
 - 10.2.1 RISING DEPENDENCE ON RAPID MICROFLUIDIC MOLECULAR DIAGNOSTICS TO DRIVE GROWTH 137
 - 10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 138
 - 10.3.1 STRONG ADOPTION OF MICROFLUIDIC TECHNOLOGIES FOR PRECISE FORMULATION, NANOPARTICLE PRODUCTION, AND TOXICITY TESTING TO DRIVE GROWTH 138
 - 10.4 ACADEMIC & RESEARCH INSTITUTES 139
 - 10.4.1 INVESTMENTS IN BIOMEDICAL & LIFE SCIENCE RESEARCH TO DRIVE GROWTH 139
- 11 MICROFLUIDICS MARKET, BY REGION 141
 - 11.1 INTRODUCTION 142
 - 11.2 NORTH AMERICA 142
 - 11.2.1 US 147
 - 11.2.1.1 Expansion of applications beyond traditional diagnostics to drive market 147
 - 11.2.2 CANADA 149
 - 11.2.2.1 Government funding and collaborative ecosystems to support growth 149
 - 11.3 EUROPE 151
 - 11.3.1 GERMANY 155
 - 11.3.1.1 Ongoing investments in semiconductors and microelectronics to drive market 155
 - 11.3.2 FRANCE 157
 - 11.3.2.1 Rising demand for advanced lab-on-chip and organ-on-chip solutions to drive market 157
 - 11.3.3 UK 159
 - 11.3.3.1 Rising cases of chronic diseases and increasing demand for POC testing to boost demand 159
 - 11.3.4 ITALY 161
 - 11.3.4.1 Shift toward cost-efficient microfluidic platforms for diagnostics, environmental testing, and advanced biomedical research to drive market 161
 - 11.3.5 SPAIN 163
 - 11.3.5.1 Increasing demand for accessible point-of-care and lab-on-chip solutions to drive market 163
 - 11.3.6 REST OF EUROPE 165
 - 11.4 ASIA PACIFIC 167
 - 11.4.1 CHINA 172
 - 11.4.1.1 Government support and strategic partnerships to drive market 172
 - 11.4.2 JAPAN 174
 - 11.4.2.1 Government support, innovation, and industry-academia collaboration to drive growth 174
 - 11.4.3 INDIA 176
 - 11.4.3.1 Growing biotech startup ecosystem and research from premier institutions to drive market 176
 - 11.4.4 AUSTRALIA 178
 - 11.4.4.1 Innovation ecosystem, R&D strength, and precision engineering to support growth 178
 - 11.4.5 SOUTH KOREA 180
 - 11.4.5.1 Advanced research, global partnerships, and next-gen technologies to drive market 180
 - 11.4.6 REST OF ASIA PACIFIC 182
 - 11.5 LATIN AMERICA 184
 - 11.5.1 BRAZIL 188
 - 11.5.1.1 Rising investment in healthtech and emphasis on molecular diagnostics to drive market 188
 - 11.5.2 MEXICO 190

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.5.2.1	Growing demand for advanced diagnostics and biotech innovation to drive market	190
11.5.3	REST OF LATIN AMERICA	192
11.6	MIDDLE EAST & AFRICA	194
11.6.1	GCC COUNTRIES	199
11.6.1.1	Disease burden and healthcare modernization to drive market	199
11.6.2	REST OF MIDDLE EAST & AFRICA	200
12	COMPETITIVE LANDSCAPE	203
12.1	INTRODUCTION	203
12.2	KEY PLAYER STRATEGIES/RIGHT TO WIN	203
12.3	OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN MICROFLUIDICS MARKET	203
12.4	REVENUE ANALYSIS, 2022?2024	204
12.5	MARKET SHARE ANALYSIS, 2024	205
12.6	RANKING OF KEY MARKET PLAYERS	207
12.7	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024	207
12.7.1	STARS	207
12.7.2	EMERGING LEADERS	207
12.7.3	PERVASIVE PLAYERS	208
12.7.4	PARTICIPANTS	208
12.7.5	COMPANY FOOTPRINT: KEY PLAYERS, 2024	209
12.7.5.1	Company footprint	209
12.7.5.2	Region footprint	209
12.7.5.3	Product footprint	210
12.7.5.4	Application footprint	211
12.7.5.5	End user footprint	212
?		
12.8	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024	212
12.8.1	PROGRESSIVE COMPANIES	212
12.8.2	RESPONSIVE COMPANIES	213
12.8.3	DYNAMIC COMPANIES	213
12.8.4	STARTING BLOCKS	213
12.8.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024	214
12.8.5.1	List of key startup/SME players	214
12.8.5.2	Competitive benchmarking of key startups/SMEs	214
12.9	COMPANY VALUATION & FINANCIAL METRICS	215
12.9.1	FINANCIAL METRICS	215
12.9.2	COMPANY VALUATION	216
12.10	BRAND/PRODUCT COMPARATIVE ANALYSIS	216
12.11	COMPETITIVE SCENARIO	217
12.11.1	PRODUCT LAUNCHES & APPROVALS	217
12.11.2	DEALS	218
12.11.3	EXPANSIONS	219
12.11.4	OTHER DEVELOPMENTS	219
13	COMPANY PROFILES	220
13.1	KEY PLAYERS	220
13.1.1	DANAHER CORPORATION	220
13.1.1.1	Business overview	220
13.1.1.2	Products offered	221

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.1.1.3 Recent developments 222
- 13.1.1.3.1 Deals 222
- 13.1.1.3.2 Expansions 223
- 13.1.1.4 MnM view 223
- 13.1.1.4.1 Key strengths 223
- 13.1.1.4.2 Strategic choices 223
- 13.1.1.4.3 Weaknesses & competitive threats 223
- 13.1.2 ILLUMINA, INC. 224
- 13.1.2.1 Business overview 224
- 13.1.2.2 Products offered 225
- 13.1.2.3 Recent developments 226
- 13.1.2.3.1 Product launches 226
- 13.1.2.3.2 Deals 226
- 13.1.2.4 MnM view 228
- 13.1.2.4.1 Key strengths 228
- 13.1.2.4.2 Strategic choices 228
- 13.1.2.4.3 Weaknesses & competitive threats 228
- ?
- 13.1.3 BIOMERIEUX 229
- 13.1.3.1 Business overview 229
- 13.1.3.2 Products offered 230
- 13.1.3.3 Recent developments 231
- 13.1.3.3.1 Product launches/approvals 231
- 13.1.3.3.2 Deals 232
- 13.1.3.4 MnM view 232
- 13.1.3.4.1 Key strengths 232
- 13.1.3.4.2 Strategic choices 232
- 13.1.3.4.3 Weaknesses & competitive threats 232
- 13.1.4 THERMO FISHER SCIENTIFIC INC. 233
- 13.1.4.1 Business overview 233
- 13.1.4.2 Products offered 234
- 13.1.4.3 Recent developments 235
- 13.1.4.3.1 Product launches/approvals 235
- 13.1.4.3.2 Deals 237
- 13.1.4.4 MnM view 237
- 13.1.4.4.1 Key strengths 237
- 13.1.4.4.2 Strategic choices 237
- 13.1.4.4.3 Weaknesses & competitive threats 237
- 13.1.5 ABBOTT LABORATORIES 238
- 13.1.5.1 Business overview 238
- 13.1.5.2 Products offered 239
- 13.1.5.3 MnM view 240
- 13.1.5.3.1 Key strengths 240
- 13.1.5.3.2 Strategic choices 240
- 13.1.5.3.3 Weaknesses & competitive threats 240
- 13.1.6 PARKER HANNIFIN CORP 241
- 13.1.6.1 Business overview 241

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.1.6.2 Products offered 242
- 13.1.7 SMC CORPORATION 245
 - 13.1.7.1 Business overview 245
 - 13.1.7.2 Products offered 246
 - 13.1.7.3 Recent developments 248
 - 13.1.7.3.1 Product launches 248
- 13.1.8 IDEX CORPORATION 251
 - 13.1.8.1 Business overview 251
 - 13.1.8.2 Products offered 252
 - 13.1.8.3 Recent developments 254
 - 13.1.8.3.1 Deals 254
- ?
- 13.1.9 FORTIVE 255
 - 13.1.9.1 Business overview 255
 - 13.1.9.2 Products offered 256
- 13.1.10 REVVITY, INC. 257
 - 13.1.10.1 Business overview 257
 - 13.1.10.2 Products offered 258
 - 13.1.10.3 Recent developments 258
 - 13.1.10.3.1 Deals 258
- 13.1.11 AGILENT TECHNOLOGIES, INC. 259
 - 13.1.11.1 Business overview 259
 - 13.1.11.2 Products offered 260
 - 13.1.11.3 Recent developments 261
 - 13.1.11.3.1 Product approvals/launches 261
 - 13.1.11.3.2 Deals 262
 - 13.1.11.3.3 Expansions 263
- 13.1.12 BIO-RAD LABORATORIES, INC. 264
 - 13.1.12.1 Business overview 264
 - 13.1.12.2 Products offered 265
 - 13.1.12.3 Recent developments 266
 - 13.1.12.3.1 Product launches 266
 - 13.1.12.3.2 Deals 267
- 13.1.13 BECTON, DICKINSON AND COMPANY 268
 - 13.1.13.1 Business overview 268
 - 13.1.13.2 Products offered 269
 - 13.1.13.3 Recent developments 270
 - 13.1.13.3.1 Product launches/approvals 270
 - 13.1.13.3.2 Deals 272
 - 13.1.13.3.3 Expansions 273
- 13.1.14 F. HOFFMANN-LA ROCHE LTD. 274
 - 13.1.14.1 Business overview 274
 - 13.1.14.2 Products offered 275
 - 13.1.14.3 Recent developments 275
 - 13.1.14.3.1 Product launches/approvals 275
 - 13.1.14.3.2 Deals 276
- 13.1.15 STANDARD BIOTOOLS 277

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.1.15.1	Business overview	277
13.1.15.2	Products offered	278
13.1.15.3	Recent developments	279
13.1.15.3.1	Product launches/approvals	279
13.1.15.3.2	Deals	279
?		
13.1.16	QUIDELORTHO CORPORATION	280
13.1.16.1	Business overview	280
13.1.16.2	Products offered	281
13.1.16.3	Recent developments	282
13.1.16.3.1	Product approvals	282
13.1.16.3.2	Deals	282
13.1.16.3.3	Expansions	283
13.1.17	AIGNEP S.P.A.	284
13.1.17.1	Business overview	284
13.1.17.2	Products offered	284
13.1.17.3	Recent developments	285
13.1.17.3.1	Deals	285
13.1.18	DOLOMITE MICROFLUIDICS	286
13.1.18.1	Business overview	286
13.1.18.2	Products offered	286
13.1.18.3	Recent developments	289
13.1.18.3.1	Product launches	289
13.1.18.3.2	Deals	289
13.1.18.3.3	Other developments	290
13.1.19	ELVEFLOW	291
13.1.19.1	Business overview	291
13.1.19.2	Products offered	291
13.2	OTHER PLAYERS	293
13.2.1	NANOSTRING TECHNOLOGIES	293
13.2.2	INNOVATIVE BIOCHIPS, LLC	294
13.2.3	FLUIDIC ANALYTICS	295
13.2.4	HORIBA	296
13.2.5	MICRONIT B.V.	297
13.2.6	EMULATE, INC.	298
13.2.7	SPHERE BIO	299
13.2.8	ZEON CORPORATION	300
13.2.9	QIAGEN N.V.	301
14	RESEARCH METHODOLOGY	302
14.1	RESEARCH DATA	302
14.2	RESEARCH DESIGN	303
14.2.1	SECONDARY RESEARCH	303
14.2.1.1	Objectives of secondary research	304
14.2.1.2	Key data from secondary sources	305
14.2.2	PRIMARY RESEARCH	305
14.2.2.1	Objectives of primary research	306
14.2.2.2	Key industry insights	307

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.3	MARKET SIZE ESTIMATION METHODOLOGY	308
14.3.1	BOTTOM-UP APPROACH	309
14.3.1.1	Approach 1: Company revenue estimation approach	310
14.3.1.2	Approach 2: Customer-based market estimation	310
14.3.1.3	Approach 3: Primary interviews	311
14.3.2	TOP-DOWN APPROACH	311
14.4	MARKET BREAKDOWN AND DATA TRIANGULATION	313
14.5	MARKET SHARE ASSESSMENT	314
14.6	RESEARCH ASSUMPTIONS	314
14.7	RESEARCH LIMITATIONS	314
14.8	RISK ASSESSMENT	315
15	APPENDIX	316
15.1	DISCUSSION GUIDE	316
15.2	KNOWLEDGESTORE: MARKET SAND MARKETS' SUBSCRIPTION PORTAL	322
15.3	CUSTOMIZATION OPTIONS	324
15.4	RELATED REPORTS	324
15.5	AUTHOR DETAILS	325

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Microfluidics Market by Product (Chip, Sensor, Valve, Pump, Needle), Material (Silicon, Polymer), Application [Diagnostics (Clinical, PoC), Research (Proteomics, Genomics, Cell), Therapeutics (Drug Delivery Wearables)], End User - Global forecast to 2030

Market Report | 2026-01-30 | 326 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

2026-03-07

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com